Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canada-based drug delivery company IntelGenx and Ireland-based specialty pharmaceutical company Circ Pharma have formed a partnership, pursuant to which IntelGenx will formulate, manufacture and supply to Circ, and Circ will develop and commercialize, a novel drug product for the treatment of hyperlipidemia.
Subscribe to our email newsletter
Under the terms of the agreement, Circ Pharma will fund the development of the product and IntelGenx will receive royalties from the product’s sales. IntelGenx will use its proprietary Versatab technology to formulate the product.
This is said to be the first product in a series of Circ Pharma’s controlled release lipid lowering agents specifically designed to target the absorption of drug in order to reduce the effective dose and potentially lower the side effects. The product is expected to reach the market in 2012.
Horst Zerbe, president and CEO of IntelGenx, said: “We are very pleased about this collaboration with Circ Pharma. It is another testament to our drug development capabilities. We are looking forward to a productive and successful relationship with Circ Pharma.”